GlassScriptPhysician profile
Judith A Jackson
NPI 1871961250
$10,652.89
in general payments reported to CMS, 2019-2025
33 companies · $524 in 2025
The $524 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $8,651 · 2022: $536 · 2023: $537 · 2024: $404 · 2025: $524.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,466.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,465.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $8,553.74 | 2021-2025 | |
| Allergan, INC. | $750.00 | 2021 | |
| Novo Nordisk INC | $161.28 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $145.72 | 2022-2025 | |
| Lilly USA, LLC | $116.68 | 2022-2025 | Zepbound, Mounjaro, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.37 | 2022-2025 | Tradjenta, Jardiance |
| Antares Pharma, INC. | $71.27 | 2022-2023 | Nocdurna, Tlando, Xyosted |
| Lundbeck LLC | $68.58 | 2023-2025 | Rexulti, Vyepti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $58.11 | 2022-2023 | |
| Insulet Corporation | $50.66 | 2022-2024 | Omnipod |
| Otsuka America Pharmaceutical, INC. | $48.94 | 2023-2025 | Rexulti, Abilify Asimtufii |
| Sanofi-Aventis U.S. LLC | $47.07 | 2025 | |
| Exact Sciences Corporation | $44.30 | 2023-2024 | Cologuard Collection Kit |
| Almatica Pharma LLC | $40.14 | 2023 | Loreev Xr |
| Bayer Healthcare Pharmaceuticals INC. | $36.53 | 2022-2023 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $35.36 | 2021-2025 | Freestyle Libre 3 |
| Neurocrine Biosciences, INC. | $31.27 | 2025 | |
| Axsome Therapeutics, INC. | $29.42 | 2023 | Auvelity |
| Biohaven Pharmaceutical Holding Company LTD. | $28.32 | 2022 | |
| Vanda Pharmaceuticals INC. | $23.10 | 2025 | Fanapt |
| Novartis Pharmaceuticals Corporation | $22.79 | 2025 | |
| Corium, LLC | $22.03 | 2023 | Azstarys |
| Janssen Pharmaceuticals, INC | $20.49 | 2022 | |
| Corcept Therapeutics | $19.13 | 2025 | Korlym |
| Grt US Holding, INC. | $18.58 | 2022 | |
| Tandem Diabetes Care, INC. | $18.41 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Shield Therapeutics INC | $17.66 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.58 | 2024 | Xifaxan |
| Glaxosmithkline, LLC. | $16.03 | 2022 | |
| Amneal Pharmaceuticals LLC | $15.27 | 2023 | Unithroid |
| Kowa Pharmaceuticals America, INC. | $14.61 | 2025 | Zoryve |
| Sanofi Pasteur INC. | $13.96 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $13.49 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Judith Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.